Founded with a mission to revolutionize cancer treatment, Cytosolix focuses on developing novel small molecule therapies that improve the efficacy and safety of cancer drugs. The company's core innovation, the Tumor Activated Permeability System, creates weakly-acidic derivatives of known oncology drugs. These derivatives enhance uptake by cancer cells while minimizing impact on healthy cells, allowing for safer and more effective treatments. Cytosolix offers both oral and intravenous (IV) formulations, targeting the oncology market with a particular emphasis on overcoming dose-limiting toxicities.
Cytosolix has garnered attention from notable investors and industry experts due to its groundbreaking approach to cancer therapy. The company has achieved significant milestones in preclinical studies, demonstrating the potential to transform standard cancer treatment protocols. By focusing on tumor acidity as a therapeutic target, Cytosolix aims to reduce side effects and improve patient outcomes, making a substantial impact on the field of oncology.
